Two column charts analyzing the rate of acquisitions of biotech companies in 2026. Eli Lilly leads the group with 12 announced deals and more than $31.5 billion in cumulative deal value.

(Please use a modern browser to see the interactive version of this visualization)

Note: Eli Lilly has not disclosed the financial terms of its June acquisition of 4E Therapeutics.

Chart: Ben Fidler, Gwendolyn Wu / BioPharma DiveSource: BioPharma Dive